27 unknown. 27 Phase 2, 8 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Unknown 27 |
| Phase 3 | 8 | Unknown 8 |
| Phase 1 | 4 | Unknown 4 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone)) - Urinary Tract Infections, Pyelonephritis | Phase 2 | Unknown | NeuroRx, Inc. | 13 | 2024-03-31 | 2023-11-13 |
| Assessment of Safety and Efficacy of SGLT2is Among LN Patients Dapagliflozin 10mg Tab orally once daily - Lupus Nephritis | Phase 1 / Phase 2 | Unknown | Ain Shams University | 50 | 2023-12-01 | 2023-11-02 |
| A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease Placebo of SC0062, SC0062 low dose, SC0062 medium dose - Diabetic Kidney Disease, IgA Nephropathy | Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 255 | 2023-05-23 | 2025-01-07 |
| A Study of Telitacicept in Lupus Nephritis Telitacicept 240 mg, Telitacicept 160 mg, Placebo - Lupus Nephritis | Phase 2 | Unknown | RemeGen Co., Ltd. | 120 | 2023-04-17 | 2024-09-23 |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy Telitacicept - IgA Nephropathy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-03-01 | 2023-02-24 |
| Use of Baricitenib to Maintain of Remission Baricitinib 4 MG, Baricitinib 2 MG, MMF - Lupus or SLE, Nephritis | Phase 2 / Phase 3 | Unknown | Assiut University | 80 | 2022-06-01 | 2023-01-17 |
| Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Sirolimus - Lupus Nephritis, Immunosuppression | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 20 | 2021-06-30 | 2021-05-19 |
| A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis SHR-1314, Placebo - Lupus Nephritis | Phase 2 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 60 | 2021-06-28 | 2021-06-11 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) - Systemic Lupus Erythematosus | Phase 2 | Unknown | Hanyang University Seoul Hospital | 10 | 2019-09-26 | 2021-04-08 |
| Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care - IgA Nephropathy at High Risk of Developing ESRD | Phase 2 / Phase 3 | Unknown | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 60 | 2019-07-04 | 2024-09-25 |
| Mesenchymal Stromal Cells (MSC´s) in Renal Lupus MSC treatment, Standard of Care, Placebo - Lupus Erythematosus, Systemic, Lupus Glomerulonephritis | Phase 2 | Unknown | Universidad de los Andes, Chile | 39 | 2019-04-02 | 2023-02-08 |
| Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN) Mesenchymal stem cells, Mycophenolate Mofetil, Placebo of Mesenchymal stem cells - Lupus Nephritis | Phase 2 | Unknown | Lingyun Sun | 230 | 2018-08-01 | 2018-07-10 |
| Fecal Microbiota Transplantation for Refractory IgA Nephropathy Fecal microbiota transplantation - IgA Nephropathy | Phase 2 | Unknown | Air Force Military Medical University, China | 30 | 2017-11-22 | 2018-08-21 |
| The Iguratimod Effect on Lupus Nephritis (IGeLU) Iguratimod, Cyclophosphamide, Azathioprine - Lupus Nephritis | Phase 2 | Unknown | RenJi Hospital | 120 | 2017-09-07 | 2018-12-19 |
| Valproic Acid for Idiopathic Nephrotic Syndrome Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 / Phase 3 | Unknown | Universitair Ziekenhuis Brussel | 15 | 2016-10-01 | 2017-06-20 |
| Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy Prednisolone, Reh-acteoside - IGA Nephropathy | Phase 2 / Phase 3 | Unknown | Sun Yat-sen University | 75 | 2016-05-01 | 2016-02-02 |
| ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study ACTHAR Gel (adrenocorticotropic hormone) - Sarcoidosis, Hypercalcemia Due to Sarcoidosis | Phase 2 / Phase 3 | Unknown | Albany Medical College | 10 | 2015-02-01 | 2015-01-26 |
| A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy steroid & Cyclosporin - Idiopathic Membranous Nephropathy, Proteinuria | Phase 2 | Unknown | Sun Yat-sen University | 180 | 2014-06-01 | 2014-07-01 |
| A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Methylprednisolone(intravenously in the 1st-2nd-3rd month ), Methylprednisolone(intravenously in the 1st-3rd-5th month) - Glomerulonephritis, IGA, Peripapillary Crescent | Phase 2 | Unknown | Sun Yat-sen University | 180 | 2014-06-01 | 2015-03-03 |
Showing 20 of 27. Sign in to see all of them.
Lupus Nephritis (15) · Glomerulonephritis, IGA (6) · Lupus Erythematosus, Systemic (5) · Glomerulonephritis (2) · Proteinuria (2) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1) · Depression (1) · Diabetic Nephropathies (1) · Gastroesophageal Reflux (1)
Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Kidney Diseases (27) · Male Urogenital Diseases (27) · Urogenital Diseases (27) · Urologic Diseases (27) · Immune System Diseases (25) · Autoimmune Diseases (24) · Glomerulonephritis (23) · Connective Tissue Diseases (16) · Skin and Connective Tissue Diseases (16) · Lupus Erythematosus, Systemic (11) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4)
Cyclophosphamide (4) · Prednisolone (2) · Steroids (2) · telitacicept (2) · Adrenocorticotropic Hormone (1) · Azathioprine (1) · Calcitriol (1) · Clinical Coding (1) · Cycloserine (1) · Cyclosporine (1) · Fecal Microbiota Transplantation (1) · Immunosuppressive Agents (1) · Lurasidone Hydrochloride (1) · Mycophenolic Acid (1) · RC-18 (1)
Sun Yat-sen University (3) · Peking Union Medical College Hospital (2) · Ain Shams University (1) · Air Force Military Medical University, China (1) · Albany Medical College (1) · All Natural Medicine Clinic, LLC (1) · Assiut University (1) · Biocity Biopharmaceutics Co., Ltd. (1) · CytoMed & Beike (1) · Guang'anmen Hospital of China Academy of Chinese Medical Sciences (1) · Guilan University of Medical Sciences (1) · Hanyang University Seoul Hospital (1) · Kinki University (1) · Lingyun Sun (1) · Nanjing Medical University (1)
China (14) · Egypt (2) · South Korea (2) · United States (2) · Belgium (1) · Chile (1) · Iran (1) · Japan (1)
Zongpei Jiang, M.D. & Ph.D. (2) · Alireza Amir Maafi, MD Student (1) · Chan-Bum Choi, M.D.,Ph.D. (1) · Cherry Kamel, Professor (1) · Chunde Bao, MD (1) · Fengchun Zhang, MD (1) · Fernando F E, MD (1) · Howaida Al-Shennawi, Professor (1) · Jianghua Chen, Prof (1) · Jie Wang (1) · Lingyun Sun, M.D. (1) · Manal Hassanien, MD (1) · Marc A Judson, MD (1) · Peter Janssens, MD (1)
PMID 38299639, PMID 28478399, PMID 30428931, PMID 31907076, PMID 34380536, PMID 34778952, PMID 35062886, PMID 38334499, PMID 39462310, PMID 40465397, PMID 42001190